Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that affects approximately 400,000 people in the United States and 1 million people between 16 and 65 years of age worldwide. (1) It is a neurodegenerative pathology that can be characterized by a course of demyelination-mediated relapses and remissions, superimposed on gradual neurologic deterioration, resulting in a clinical course that is unpredictable in progression and severity. (1)